8-K: Crinetics Pharmaceuticals Unveils Promising Preclinical Data and Strategic Pipeline Updates at R&D Day

Crinetics Pharmaceuticals, Inc. presented positive preclinical data for its early-stage pipeline assets, CRN12755 for Graves disease, CRN10329 for ADPKD, and CRN09682 for SST2+ tumors, outlining strategic next steps and clinical development plans.

Summary

• Crinetics Pharmaceuticals hosted an R&D Day on June 26, 2025, providing updates on its early-stage pipeline and portfolio strategy to drive long-term value.
• CRN12755, a Thyroid Stimulating Hormone Receptor (TSHR) antagonist for Graves disease (including Graves hyperthyroidism and Graves orbitopathy/Thyroid Eye Disease, TED), showed preclinical data where it decreased TSAb-stimulated thyroid hormone (T4) in a rat model and reduced hyaluronic acid and IL-6 production in Graves Orbital Fibroblasts (GOFs) from TED patients.
• CRN10329, an SST3 agonist for autosomal dominant polycystic kidney disease (ADPKD), was identified as a preclinical leading development candidate. Preclinical data showed it decreased cystic index, cellular proliferation, kidney weight, and aberrant expression of renal tubular injury markers in a mouse model of ADPKD.
• CRN09682, a nonpeptide drug conjugate (NDC) for metastatic or locally advanced SST2-positive neuroendocrine tumors (NETs) and other SST2-expressing solid tumors, demonstrated potency, selectivity, internalization, and dose-dependent anti-tumor activity in different mouse tumor growth models without a decrease in body weight.
• The company provided additional details regarding the trial design of its Phase 1/2 study, BRAVESST2, for CRN09682, expecting to enroll 3-6 patients per cohort in Phase 1 dose escalation and up to 150 participants across both Phase 1 and Phase 2.
• Crinetics highlighted its deep pipeline with 2 late-stage programs (Paltusotine and Atumelnant) in 4 indications, and a strong financial position with $1.3 billion of cash, cash equivalents, and investments.
• The company's strategy focuses on early derisking with biomarker validation from discovery through approval, tailoring ligands to regulate dynamic GPCR behaviors, and leveraging its nonpeptide drug conjugate platform for broad indication potential.

Sentiment

Score: 8

Explanation: The document presents strong positive preclinical data for multiple pipeline candidates, outlines clear strategic development plans, and highlights a robust financial position. The tone is confident and forward-looking, emphasizing potential for significant patient impact and market opportunity. No major negative news or setbacks were disclosed.

Positives

• Positive preclinical data for CRN12755 demonstrated a decrease in TSAb-stimulated thyroid hormone (T4) in a rat model and reduced hyaluronic acid and IL-6 production in TED patient-derived GOFs, indicating potential for a single, oral therapy for Graves disease.
• CRN10329 showed promising preclinical results in an ADPKD mouse model, decreasing cystic index, cellular proliferation, kidney weight, and aberrant expression of renal tubular injury markers, positioning it as a potential new standard of care.
• CRN09682 exhibited dose-dependent anti-tumor activity and induced tumor regression in mouse models without significant body weight loss, suggesting a favorable efficacy and safety profile for SST2+ tumors.
• The Nonpeptide Drug Conjugate (NDC) platform is designed to selectively target and deliver cytotoxic payloads to cells of interest, offering broad indication potential beyond NETs to other SST2+ tumors.
• The company maintains a strong financial position with $1.3 billion in cash, cash equivalents, and investments, supporting ongoing research and development.
• Crinetics has a deep pipeline with two late-stage programs (Paltusotine and Atumelnant) in 4 indications, alongside 4 candidates in preclinical development, indicating robust future growth potential.
• Paltusotine has an upcoming PDUFA date in September 2025, signaling a potential near-term commercial launch and revenue generation.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that may cause actual results to differ materially.
• Topline and initial data reported from clinical studies may change following a more comprehensive review and may not accurately reflect complete results.
• Interim or preclinical results of a clinical trial do not necessarily predict final results, and clinical outcomes may materially change as patient enrollment continues or more data become available.
• There is a possibility of unfavorable new clinical data and further analyses of existing clinical data.
• Potential for delays in the commencement, enrollment, and completion of clinical trials and the reporting of data therefrom.
• Dependence on third parties in connection with product manufacturing, research, and preclinical and clinical testing.
• Uncertainty regarding the success of clinical trials and nonclinical studies for product candidates.
• Regulatory developments in the United States and foreign countries could impact approval timelines or requirements.
• Risk of unexpected adverse side effects or inadequate efficacy of product candidates that may limit their development, regulatory approval, and/or commercialization.
• Challenges in obtaining and maintaining intellectual property protection for product candidates.
• Capital resources may be used sooner than expected, potentially requiring additional financing.
• Actual results could differ materially from those projected in the forward-looking statements.

Future Outlook

Crinetics Pharmaceuticals aims to advance standards of care in endocrine science and expand patient reach into new therapeutic frontiers. The company anticipates its first commercial launch this year with Paltusotine (PDUFA in September 2025) and expects sales-funded growth, pipeline expansion, and potential international launches in 2026 and beyond. For CRN09682, the Phase 1/2 BRAVESST2 trial is expected to enroll up to 150 participants across both phases, with data from the dose escalation phase informing the recommended expansion dose. The company also plans IND submissions and Phase 1 studies for CRN12755 and CRN10329, and continued expansion of its NDC discovery pipeline.

Management Comments

• "Crinetics is Well-Positioned to Advance Standards of Care With Endocrine Science." R. Scott Struthers, Ph.D., Founder & Chief Executive Officer
• "Every molecule Crinetics moves into the clinic is designed to exceed a high bar for selectivity, drug exposure and drug-like properties." Stephen Betz, Ph.D., Founder & Chief Scientific Officer
• "Patient engagement is in our DNA, with nearly two decades of relationship building that began well before our work in the clinic."
• "TSHR Antagonist: Has Potential to Be a Single, Oral Therapy to Treat Graves Hyperthyroidism and Treat/Prevent Orbitopathy (TED)." Rick Grimes, Global Product Leader, TSH
• "CRN10329 has the Potential to be Standard of Care for ADPKD." Stephen Betz, Ph.D., Founder & Chief Scientific Officer
• "CRN09682 is a First-in-Class Therapy Designed to Selectively Target and Deliver MMAE to SST2-Expressing Tumor Cells." Stacey Harte, Global Product Leader, CRN09682
• "Together, [Paltusotine and CRN09682] may offer additional benefit through co-administration, potentially broadening therapeutic impact."

Industry Context

The document highlights significant unmet medical needs in Graves disease, Autosomal Dominant Polycystic Kidney Disease (ADPKD), and neuroendocrine tumors (NETs). Current standard-of-care treatments for these conditions often present limitations such as significant side effects, burdensome administration, or incomplete efficacy. Crinetics' pipeline candidates (CRN12755, CRN10329, CRN09682) are positioned as novel, potentially superior oral therapies or targeted treatments designed to address these gaps, offering improved safety, efficacy, and convenience compared to existing options like antithyroid drugs (ATDs), Teprotumumab, Tolvaptan, or traditional chemotherapies and peptide receptor radionuclide therapies (PRRT) for NETs. This strategic focus aims to disrupt established treatment paradigms and capture significant market share in these therapeutic areas.

Comparison to Industry Standards

• **Graves Disease (CRN12755):** Current standard treatments for Graves hyperthyroidism, such as Antithyroid Drugs (ATDs), carry risks including liver injury (~3%) and agranulocytosis (~0.3%), and do not address Graves Orbitopathy (TED). Ablative therapies (Radioactive Iodine, Thyroidectomy) lead to permanent hypothyroidism. For TED, Teprotumumab (an anti-IGF-1R mAb) reduces proptosis but is associated with hearing impairment (10-20%) and hyperglycemia (10%), and requires burdensome intravenous dosing. CRN12755, as a potential oral TSHR antagonist, aims to offer rapid hyperthyroidism control with thyroid preservation, simultaneous treatment/prevention of orbitopathy, and an improved safety profile without the adverse effects of ATDs or anti-IGF-1R therapies.
• **Autosomal Dominant Polycystic Kidney Disease (ADPKD) (CRN10329):** Tolvaptan, the current standard-of-care, is used by less than 10% of patients due to modest efficacy and significant side effects, including a boxed warning for acute liver injury, increased urination, thirst, and dehydration. CRN10329, an SST3 agonist, is positioned to offer potentially more effective impact on total kidney volume (TKV) and eGFR decline, with an expected well-tolerated safety profile and once-daily oral dosing, aiming to be a superior alternative to Tolvaptan.
• **Neuroendocrine Tumors (NETs) (CRN09682):** Existing treatments for metastatic NENs, including Somatostatin Receptor Ligands (SRLs), Kinase/mTOR inhibitors, Peptide Receptor Radionuclide Therapy (PRRT), and Chemotherapy, offer variable tumor regression, side effects, and durations of response. CRN09682, an SST2-targeted nonpeptide drug conjugate, is designed to selectively deliver a potent cytotoxic payload (MMAE) to tumor cells, aiming for rapid tumor cell death and regression. This approach seeks to improve efficacy for higher-grade disease and offer a better benefit/risk profile compared to current modalities, addressing limitations such as radiation safety concerns and variable tumor penetration of PRRT.

Stakeholder Impact

• **Shareholders:** The positive preclinical data for multiple pipeline assets, combined with a robust pipeline and upcoming regulatory milestones, could enhance investor confidence and potentially lead to an increase in share price. The strong cash position provides financial stability and reduces immediate dilution risk.
• **Patients:** The development of novel, potentially more effective, and safer oral therapies for Graves disease, ADPKD, and NETs could significantly improve quality of life and treatment outcomes for patients suffering from these conditions, addressing current unmet medical needs.
• **Employees:** Continued progress in research and development, coupled with potential commercialization successes, could lead to company growth, increased job opportunities, and enhanced career stability.
• **Healthcare Providers:** New treatment options could provide physicians with more effective and convenient tools to manage complex endocrine and oncology conditions, potentially improving patient adherence and outcomes.

Next Steps

• IND Submission for TSH Antagonist (CRN12755).
• Phase 1 Healthy Volunteer Study for TSH Antagonist (CRN12755) with early proof-of-concept using thyroid biomarkers (TSH, T3, T4).
• IND Enabling Studies and Activities for SST3 Agonist (CRN10329).
• IND Clearance for SST3 Agonist (CRN10329).
• Phase 1 Healthy Volunteer Study for SST3 Agonist (CRN10329).
• Enrolling Patients in Phase 1/2 Study for CRN09682 (BRAVESST2).
• Exploring Additional Tumor Types with CRN09682 Beyond NETs.
• Data from Dose Escalation Portion of Phase 1/2 Study for CRN09682.
• Expansion of Crinetics NDC Discovery Pipeline.
• PDUFA Date for Paltusotine (September 2025).
• CHMP Opinion for Paltusotine (1H 2026).
• Phase 3 for Paltusotine (2H 2025).
• Phase 3 in Adult for Atumelnant (2H 2025).
• Phase 2/3 in Pediatric for Atumelnant (2H 2025).
• Phase 2/3 for Atumelnant (2H 2025).
• IND for PTH antagonist.
• Oral GLP-1 nonpeptide Candidate Selection.
• Oral GIP nonpeptide Candidate Selection.
• Potential US Launch 2025 (Paltusotine).
• Potential International Launches 2026 & Beyond.

Key Dates

Recommendation

Keywords

Pharmaceuticals, Biotechnology, Drug Development, Clinical Trials, Preclinical Data, Graves Disease, Thyroid Eye Disease, ADPKD, Neuroendocrine Tumors, Nonpeptide Drug Conjugate, TSHR antagonist, SST3 agonist, SST2 agonist, Oncology, Endocrinology, Rare Diseases, Pipeline, Crinetics Pharmaceuticals